Bouter, Yvonne

[["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.contributor.author","Bakrania, Preeti"],["dc.contributor.author","Hall, Gareth"],["dc.contributor.author","Bouter, Yvonne"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Beindorff, Nicola"],["dc.contributor.author","Cowan, Richard"],["dc.contributor.author","Davies, Sarah"],["dc.contributor.author","Price, Jemma"],["dc.contributor.author","Mpamhanga, Chido"],["dc.contributor.author","Love, Elizabeth"],["dc.contributor.author","Bayer, Thomas A."],["dc.date.accessioned","2021-12-01T09:20:48Z"],["dc.date.available","2021-12-01T09:20:48Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1038/s41380-021-01385-7"],["dc.identifier.pii","1385"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94277"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1476-5578"],["dc.relation.issn","1359-4184"],["dc.title","Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","601"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.lastpage","603"],["dc.bibliographiccitation.volume","143"],["dc.contributor.author","Bouter, Yvonne"],["dc.contributor.author","Liekefeld, Hendrik"],["dc.contributor.author","Pichlo, Steffen"],["dc.contributor.author","Westhoff, Anna Celine"],["dc.contributor.author","Fenn, Lydia"],["dc.contributor.author","Bakrania, Preeti"],["dc.contributor.author","Bayer, Thomas A."],["dc.date.accessioned","2022-05-02T08:09:41Z"],["dc.date.available","2022-05-02T08:09:41Z"],["dc.date.issued","2022"],["dc.description.sponsorship","Georg-August-Universität Göttingen"],["dc.identifier.doi","10.1007/s00401-022-02418-3"],["dc.identifier.pii","2418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107436"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","1432-0533"],["dc.relation.issn","0001-6322"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","17338"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Antonios, Gregory"],["dc.contributor.author","Borgers, Henning"],["dc.contributor.author","Richard, Bernhard Clemens"],["dc.contributor.author","Brauss, Andreas"],["dc.contributor.author","Meissner, Julius"],["dc.contributor.author","Weggen, Sascha"],["dc.contributor.author","Pena, Vladimir"],["dc.contributor.author","Pillot, Thierry"],["dc.contributor.author","Davies, Sarah L."],["dc.contributor.author","Bakrania, Preeti"],["dc.contributor.author","Matthews, David"],["dc.contributor.author","Brownlees, Janet"],["dc.contributor.author","Bouter, Yvonne"],["dc.contributor.author","Bayer, Thomas A."],["dc.date.accessioned","2018-11-07T09:47:52Z"],["dc.date.available","2018-11-07T09:47:52Z"],["dc.date.issued","2015"],["dc.description.abstract","Full-length A beta 1-42 and A beta 1-40, N-truncated pyroglutamate A beta 3-42 and A beta 4-42 are major variants in the Alzheimer brain. A beta 4-42 has not been considered as a therapeutic target yet. We demonstrate that the antibody NT4X and its Fab fragment reacting with both the free N-terminus of A beta 4-x and pyroglutamate A beta 3-X mitigated neuron loss in Tg4-42 mice expressing A beta 4-42 and completely rescued spatial reference memory deficits after passive immunization. NT4X and its Fab fragment also rescued working memory deficits in wild type mice induced by intraventricular injection of A beta 4-42. NT4X reduced pyroglutamate A beta 3-x, A beta x-40 and Thioflavin-S positive plaque load after passive immunization of 5XFAD mice. A beta 1-x and A beta x-42 plaque deposits were unchanged. Importantly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeutically beneficial in Alzheimer mouse models showing that N-truncated A beta starting with position four in addition to pyroglutamate A beta 3-x is a relevant target to fight Alzheimer's disease."],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1038/srep17338"],["dc.identifier.isi","000365638800001"],["dc.identifier.pmid","26626428"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12643"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35186"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]